{"product_id":"harvard-dementia-a-comprehensive-update-2025","title":"Harvard Dementia A Comprehensive Update 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: primary care physicians, psychologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWho Should Attend\u003c\/p\u003e\n\u003cp\u003eNurses\u003c\/p\u003e\n\u003cp\u003ePrimary Care Physicians\u003c\/p\u003e\n\u003cp\u003eSpecialty Physicians\u003c\/p\u003e\n\u003cp\u003ePsychologists\u003c\/p\u003e\n\u003cp\u003ePhysician Assistants\u003c\/p\u003e\n\u003cp\u003eNurse Practitioners\u003c\/p\u003e\n\u003cp\u003eSocial Workers\u003c\/p\u003e\n\u003cp\u003eOther\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this activity, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eDescribe current understanding of epidemiology, risk factors, pathobiology, societal costs, clinical differences, gaps in knowledge, and challenges in distinguishing and managing the spectra of normal cognitive aging, mild cognitive impairment (MCI), Alzheimer’s disease (AD), and other neurodegenerative dementias.\u003c\/p\u003e\n\u003cp\u003eDistinguish pre-clinical AD, MCI due to AD\/prodromal AD, and AD dementia phases.\u003c\/p\u003e\n\u003cp\u003eSummarize tiered diagnostic and management approaches, and future experimental therapeutics strategies under consideration for risk reduction, prevention, diagnosis, and treatment of the AD spectrum.\u003c\/p\u003e\n\u003cp\u003eDifferentiate, based on neuropathology, affected neural systems, clinical criteria and biomarkers, AD and its atypical variants from other common dementias including Dementia with Lewy Bodies (DLB), Vascular Cognitive Impairment (VCI)\/Vascular-Ischemic Dementia, Frontotemporal Degeneration (FTD), Parkinson’s disease with Dementia (PDD), Parkinson’s-Plus Syndromes and less common dementias.\u003c\/p\u003e\n\u003cp\u003eIdentify and explain the importance of evidence-based and coordinated individualized approaches to the evaluation and management of MCI, AD, and neurodegenerative dementias that stress combining: (i) early and accurate detection, assessment, and monitoring; (ii) psycho-education and non-pharmacological interventions; (iii) pharmacological strategies; and (iv) caregiver, psychosocial\/environmental, quality of life, ethical, medico-legal and end-of-life considerations.\u003c\/p\u003e\n\u003cp\u003eApply data-supported diagnostic, behavioral, pharmacological, and environmental strategies, including appropriate and tiered use of cognitive tests\/measures, labs, and imaging studies\/biomarkers; and delineation of expectations, roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings) and treatment nuances in the interdisciplinary management of CI, AD, and neurodegenerative dementias.\u003c\/p\u003e\n\u003cp\u003eDemonstrate neural processes and functional networks that support perception and cognitive systems including memory, language, attentional, frontal\/executive, visuospatial, and motor systems.\u003c\/p\u003e\n\u003cp\u003eExplain the roles of office-based screening instruments, mental status exam (MSE), and neuropsychological evaluation in the diagnosis and management of dementia; develop efficient approaches to MSE and use of screening instruments (e.g. MOCA); and interpret and compare cognitive testing\/neuropsychological performance patterns for different conditions and clinical syndromes (e.g. MCI, AD, FTD, primary progressive aphasias, posterior cortical atrophy, DLB).\u003c\/p\u003e\n\u003cp\u003eUtilize appropriate laboratory tests, imaging studies, and neuropsychological testing for the diagnosis of dementia in clinical practice; incorporate appropriate use of clinical biomarkers (e.g. CSF a-beta\/tau, MRI, FDG- and Amyloid-PET) in evaluation of neurodegenerative dementias to differentiate AD and non-AD processes; and explain clinical versus research use, and apply appropriate use criteria\/guidelines to the clinical use of amyloid PET imaging in the diagnosis of AD-like syndromes.\u003c\/p\u003e\n\u003cp\u003eApply data-supported pharmacologic management strategies including the roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings), and potential alternatives to cholinesterase inhibitors, memantine, antipsychotics, and antidepressants in dementia and AD.\u003c\/p\u003e\n\u003cp\u003eDiscuss the important role and the challenges and risks caregivers face; describe strategies to help dementia caregivers cope and better care for themselves and patients with dementia including psychosocial counseling, community support resources, and respite care.\u003c\/p\u003e\n\u003cp\u003eIdentify delirium\/encephalopathy and Chronic Traumatic Encephalopathy (CTE) as dementia risks or entities.\u003c\/p\u003e\n\u003cp\u003eDevelop appropriate practices concerning medico-legal and safety issues surrounding patients with dementia, including capacity with regards to medical care, finances, contracts, independent living, and driving; and integrate medico-legal and safety practices to support and safeguard patients and families, and the public-at-large.\u003c\/p\u003e\n\u003cp\u003eDescribe issues related to dementia neuroethics, and implement effective practices in the long-term care\/nursing-home environment and in end-stage dementia regarding medical, legal, and ethical issues including recognition and treatment of delirium\/encephalopathy and pain, providing palliation and hospice care, and managing end-of-life issues related to dementia.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAgenda.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 AD Dementia Practical Evaluation \u0026amp; Management in Clinical Practice Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 AD Dementia Practical Evaluation \u0026amp; Management in Clinical Practice Alireza Atri, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Advances in AD Experimental Therapeutics Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Advances in AD Experimental Therapeutics Alireza Atri, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Alzheimer’s Disease \u0026amp; Related Dementias Global Perspectives and Opportunities Heather Snyder, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Alzheimer’s Disease \u0026amp; Related Dementias Global Perspectives and Opportunities Heather Snyder, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Alzheimer’s Disease Pathobiological Definitions \u0026amp; Prevention Strategies Suzanne Schindler, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Alzheimer’s Disease Pathobiological Definitions \u0026amp; Prevention Strategies Suzanne Schindler, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 From Proteinopathies to Neuroimaging \u0026amp; Biomarkers in AD ADRD Primer on Practice and Advances David Wolk, MD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 From Proteinopathies to Neuroimaging \u0026amp; Biomarkers in AD ADRD Primer on Practice and Advances David Wolk, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Full Live.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Human Cognition An Overview Brad Dickerson, MD, MMSc.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Human Cognition An Overview Brad Dickerson, MD, MMSc.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Introduction to the Course Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Memory Systems \u0026amp; Amnesia Andrew Budson, MD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Memory Systems \u0026amp; Amnesia Andrew Budson, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Mild Cognitive Impairment Prodromal AD and Beyond Ronald Petersen, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Mild Cognitive Impairment Prodromal AD and Beyond Ronald Petersen, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Neuropathology of AD ADRD A Guide for Practicing Clinicians Matthew P. Frosch, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Neuropathology of AD ADRD A Guide for Practicing Clinicians Matthew P. Frosch, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 28 Panel Discussion and Q\u0026amp;A Alireza Atri, MD, PhD; Brad Dickerson, MD, MMSc 1.mp4\u003c\/p\u003e\n\u003cp\u003eMay 28 Panel Discussion and Q\u0026amp;A Alireza Atri, MD, PhD; Brad Dickerson, MD, MMSc 2.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Assessment of Cognition in Clinical Practice Alireza Atri, MD, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Assessment of Daily Function and Neuropsychiatric Symptoms Behavior and Staging of Dementia in Practice Brad Dickerson, MD, MMSc.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Assessment of Daily Function and Neuropsychiatric Symptoms Behavior and Staging of Dementia in Practice Brad Dickerson, MD, MMSc.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Attentional and Executive Systems – Don’t Leave Home without Them Kirk Daffner, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Frontotemporal Dementias Focus on Behaviorall Executive Variants Bruce Miller, MD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Frontotemporal Dementias Focus on Behaviorall Executive Variants Bruce Miller, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Full Live.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Language Systems \u0026amp; Aphasia-Predominant Dementia Syndromes M. Marsel Mesulam, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Lewy Body Disease, and Parkinsonian \u0026amp; Sensorimotor-predominant Dementias James Galvin, MD, MPH.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Neuropsychology of Aging Sandra Weintraub, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Neuropsychology of Aging Sandra Weintraub, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Panel Discussion and Q\u0026amp;A Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Panel Discussion and Q\u0026amp;A Alireza Atri, MD, PhD; Brad Dickerson, MD, MMSc.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Practical Compensatory Strategies for Cognitive Decline Lynn Shaughnessy, PsyD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Practical Compensatory Strategies for Cognitive Decline Lynn Shaughnessy, PsyD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 29 Updates on Vascular Cognitive Impairment \u0026amp; Dementia Charles DeCarli, MD, FAAN, FAHA.mp4\u003c\/p\u003e\n\u003cp\u003eMay 29 Updates on Vascular Cognitive Impairment \u0026amp; Dementia Charles DeCarli, MD, FAAN, FAHA.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Caregiving in Dementia Impact, Consequences \u0026amp; Opportunities Mary Mittelman, DrPH.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Chronic Traumatic Encephalopathy (CTE) \u0026amp; Dementia Robert Stern, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Chronic Traumatic Encephalopathy (CTE) \u0026amp; Dementia Robert Stern, PhD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Community Advocacy and Activism For Dementias Katie Brandt, MM.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Community Advocacy and Activism For Dementias Katie Brandt, MM.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Delirium, Encephalopathies and Uncommon Dementias Jeremy Schmahmann, MD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Delirium, Encephalopathies and Uncommon Dementias Jeremy Schmahmann, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Full Live.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Morning Introductions Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Non-Pharmacological Approaches to Neuropsychiatric Symptoms and Problem Behaviors in Dementia Helen Kales, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Panel Discussion and Q\u0026amp;A Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Panel Discussion, Q\u0026amp;A and Conclusions Alireza Atri, MD, PhD; Brad Dickerson, MD, MMSc.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Pharmacological Management of Behavioral Problems in Dementia Clive Ballard, MDB ChB, MRC Psych, MD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 30 Pharmacological Management of Behavioral Problems in Dementia Clive Ballard, MDB ChB, MRC Psych, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 30 Practical \u0026amp; Ethical Considerations for Disclosure of Dementia-Related Diagnosis and Risk Jason Karlawish, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 31 Advance Care Planning \u0026amp; Management of End-stage Dementia, Pain, Palliation \u0026amp; Hospice in Long-Term Care Mary Norman, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 31 Dementia \u0026amp; The Law- Clinical Pearls on Testamentary Capacity and Undue Influence – Bruce H. Price, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 31 Dementia \u0026amp; The Law- Clinical Pearls on Testamentary Capacity and Undue Influence – Judith G. Edersheim, JD, MD.pdf\u003c\/p\u003e\n\u003cp\u003eMay 31 Driving, Home \u0026amp; Community Safety and Dementia Margaret O’Connor, PhD, ABPP CN.mp4\u003c\/p\u003e\n\u003cp\u003eMay 31 Driving, Home \u0026amp; Community Safety and Dementia Margaret O’Connor, PhD, ABPP CN.pdf\u003c\/p\u003e\n\u003cp\u003eMay 31 Full Live.mp4\u003c\/p\u003e\n\u003cp\u003eMay 31 Morning Introductions Alireza Atri, MD, PhD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 31 Panel Discussion, Q\u0026amp;A and Conclusions Alireza Atri, MD, PhD; Brad Dickerson, MD, MMSc.mp4\u003c\/p\u003e\n\u003cp\u003eMay 31 Principles \u0026amp; Practice of Mental Capacity and Competence in Dementia From Finances to Firearms Barry S. Fogel, MD.mp4\u003c\/p\u003e\n\u003cp\u003eMay 31 Principles \u0026amp; Practice of Mental Capacity and Competence in Dementia From Finances to Firearms Barry S. Fogel, MD.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405768642756,"sku":null,"price":97.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Dementia-A-Comprehensive-Update-2025.jpg?v=1784215881","url":"https:\/\/medicalcoursespro.com\/products\/harvard-dementia-a-comprehensive-update-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}